InnoCare Pharma Limited

SEHK:9969 Stock Report

Market Cap: HK$30.4b

InnoCare Pharma Future Growth

Future criteria checks 1/6

InnoCare Pharma's earnings are forecast to decline at 40.3% per annum while its annual revenue is expected to grow at 14.3% per year. EPS is expected to decline by 42.7% per annum. Return on equity is forecast to be 1.7% in 3 years.

Key information

-40.3%

Earnings growth rate

-42.68%

EPS growth rate

Biotechs earnings growth31.6%
Revenue growth rate14.3%
Future return on equity1.74%
Analyst coverage

Good

Last updated08 Apr 2026

Recent future growth updates

The InnoCare Pharma Limited (HKG:9969) Yearly Results Are Out And Analysts Have Published New Forecasts

Mar 27
The InnoCare Pharma Limited (HKG:9969) Yearly Results Are Out And Analysts Have Published New Forecasts

Earnings Update: InnoCare Pharma Limited (HKG:9969) Just Reported Its Interim Results And Analysts Are Updating Their Forecasts

Nov 16
Earnings Update: InnoCare Pharma Limited (HKG:9969) Just Reported Its Interim Results And Analysts Are Updating Their Forecasts

Recent updates

The InnoCare Pharma Limited (HKG:9969) Yearly Results Are Out And Analysts Have Published New Forecasts

Mar 27
The InnoCare Pharma Limited (HKG:9969) Yearly Results Are Out And Analysts Have Published New Forecasts

Pinning Down InnoCare Pharma Limited's (HKG:9969) P/S Is Difficult Right Now

Jan 26
Pinning Down InnoCare Pharma Limited's (HKG:9969) P/S Is Difficult Right Now

An Intrinsic Calculation For InnoCare Pharma Limited (HKG:9969) Suggests It's 45% Undervalued

Jan 06
An Intrinsic Calculation For InnoCare Pharma Limited (HKG:9969) Suggests It's 45% Undervalued

Earnings Update: InnoCare Pharma Limited (HKG:9969) Just Reported Its Interim Results And Analysts Are Updating Their Forecasts

Nov 16
Earnings Update: InnoCare Pharma Limited (HKG:9969) Just Reported Its Interim Results And Analysts Are Updating Their Forecasts

Some InnoCare Pharma Limited (HKG:9969) Shareholders Look For Exit As Shares Take 26% Pounding

Oct 14
Some InnoCare Pharma Limited (HKG:9969) Shareholders Look For Exit As Shares Take 26% Pounding

InnoCare Pharma Limited (HKG:9969) Shares Could Be 33% Below Their Intrinsic Value Estimate

Sep 19
InnoCare Pharma Limited (HKG:9969) Shares Could Be 33% Below Their Intrinsic Value Estimate

Subdued Growth No Barrier To InnoCare Pharma Limited (HKG:9969) With Shares Advancing 33%

Jul 24
Subdued Growth No Barrier To InnoCare Pharma Limited (HKG:9969) With Shares Advancing 33%

Despite Lacking Profits InnoCare Pharma (HKG:9969) Seems To Be On Top Of Its Debt

Jul 15
Despite Lacking Profits InnoCare Pharma (HKG:9969) Seems To Be On Top Of Its Debt

What InnoCare Pharma Limited's (HKG:9969) 26% Share Price Gain Is Not Telling You

Apr 22
What InnoCare Pharma Limited's (HKG:9969) 26% Share Price Gain Is Not Telling You
User avatar

Advancing Orelabrutinib And Autoimmune Therapies Will Open New Market Opportunities

Orelabrutinib's market position and expansion are set to boost revenue, supported by ongoing clinical advancements and strategic approvals.

Is There An Opportunity With InnoCare Pharma Limited's (HKG:9969) 49% Undervaluation?

Mar 17
Is There An Opportunity With InnoCare Pharma Limited's (HKG:9969) 49% Undervaluation?

InnoCare Pharma Limited (HKG:9969) Stock Rockets 32% As Investors Are Less Pessimistic Than Expected

Feb 18
InnoCare Pharma Limited (HKG:9969) Stock Rockets 32% As Investors Are Less Pessimistic Than Expected

Pinning Down InnoCare Pharma Limited's (HKG:9969) P/S Is Difficult Right Now

Dec 18
Pinning Down InnoCare Pharma Limited's (HKG:9969) P/S Is Difficult Right Now

Is InnoCare Pharma (HKG:9969) A Risky Investment?

Oct 21
Is InnoCare Pharma (HKG:9969) A Risky Investment?

Subdued Growth No Barrier To InnoCare Pharma Limited (HKG:9969) With Shares Advancing 29%

Sep 13
Subdued Growth No Barrier To InnoCare Pharma Limited (HKG:9969) With Shares Advancing 29%

Analyst Estimates: Here's What Brokers Think Of InnoCare Pharma Limited (HKG:9969) After Its Half-Yearly Report

Aug 22
Analyst Estimates: Here's What Brokers Think Of InnoCare Pharma Limited (HKG:9969) After Its Half-Yearly Report

Earnings and Revenue Growth Forecasts

SEHK:9969 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20283,632557376N/A3
12/31/20272,849128195N/A9
12/31/20262,316184204N/A7
12/31/20252,375642N/AN/AN/A
9/30/20251,427-230-162-117N/A
6/30/20251,321-209-193-145N/A
3/31/20251,225-280-292-225N/A
12/31/20241,009-441-444-366N/A
9/30/2024899-376-702-552N/A
6/30/2024781-471-835-638N/A
3/31/2024715-761-832-595N/A
12/31/2023739-631-920-665N/A
9/30/2023721-584-834-616N/A
6/30/2023757-867-892-682N/A
3/31/2023696-781-791-582N/A
12/31/2022625-887-936-566N/A
9/30/2022503-987-888-508N/A
6/30/20221,187-296-229150N/A
3/31/20221,111-78-226117N/A
12/31/20211,043-65-4167N/A
9/30/20219826049239N/A
6/30/2021102-266-464-258N/A
3/31/202152-329-444-215N/A
12/31/20201-391-424-173N/A
9/30/20201-1,853-393-148N/A
6/30/20201-2,155-320-137N/A
3/31/20201-2,148-237-108N/A
12/31/20191-2,141-155-80N/A
9/30/20192-742N/A-30N/A
6/30/20192-592N/A-17N/A
3/31/20192-571N/A-18N/A
12/31/20182-550N/A-18N/A
12/31/20170-342N/A-49N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 9969's earnings are forecast to decline over the next 3 years (-40.3% per year).

Earnings vs Market: 9969's earnings are forecast to decline over the next 3 years (-40.3% per year).

High Growth Earnings: 9969's earnings are forecast to decline over the next 3 years.

Revenue vs Market: 9969's revenue (14.3% per year) is forecast to grow faster than the Hong Kong market (8.5% per year).

High Growth Revenue: 9969's revenue (14.3% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 9969's Return on Equity is forecast to be low in 3 years time (1.7%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/04/10 14:41
End of Day Share Price 2026/04/10 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

InnoCare Pharma Limited is covered by 22 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Pei ChengChina Galaxy Securities Co., Ltd.
Peng ZouChina International Capital Corporation Limited
Jin ZhangChina International Capital Corporation Limited